Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: Six year review

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Francis, Jasmine H ^a   Abramson, David H ^a,b   Gobin, Y Pierre ^c   Marr, Brian P ^a,b   Dunkel, Ira J ^a,b   Riedel, Elyn R ^a   Brodie, Scott E ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MELPHALAN; TOPOTECAN;

ANESTHESIA INDUCTION; CHEMOSURGERY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CHOICE; ELECTRORETINOGRAM; EYE SURGERY; HUMAN; MAJOR CLINICAL STUDY; OPHTHALMIC ARTERY CHEMOSURGERY; PATIENT MONITORING; PEER REVIEW; RETINOBLASTOMA; REVIEW; STIMULUS RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL STIMULATION; DRUG EFFECTS; ELECTRORETINOGRAPHY; OPHTHALMIC ARTERY; PATHOLOGY; RETINAL NEOPLASMS; TREATMENT OUTCOME;

CARBOPLATIN; ELECTRORETINOGRAPHY; HUMANS; MELPHALAN; OPHTHALMIC ARTERY; RETINAL NEOPLASMS; RETINOBLASTOMA; TOPOTECAN; TREATMENT OUTCOME;

EID: 84906934832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084247     Document Type: Review

References (39)

1. Schaiquevich P, Buitrago E, Taich P, Torbidoni A, Ceciliano A, et al. (2012) Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 53: 4205-4212. doi:10.1167/iovs.12-9501.
2. Schaiquevich P, Buitrago E, Ceciliano A, Fandino AC, Asprea M, et al. (2012) Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. Retina (Philadelphia, Pa) 32: 387-395. doi:10.1097/IAE.0b013e31821e9f8a.
3. Marr B, Gobin PY, Dunkel IJ, Brodie SE, Abramson DH (2010) Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma. Middle East Afr J Ophthalmol 17: 207-209. doi:10.4103/0974-9233.65492.
4. Brodie SE, Pierre Gobin Y, Dunkel IJ, Kim JW, Abramson DH (2009) Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 119: 13-22. doi:10.1007/s10633-008- 9164-3.
5. Palioura S, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, et al. (2012) Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment. Pediatr Blood Cancer. doi:10.1002/pbc.24170.
6. Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, et al. (2012) Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS ONE 7: e34120. doi:10.1371/journal.pone.0034120.
7. Abramson DH (2011) Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 129: 1492-1494. doi:10.1001/archophthalmol.2011.354.
8. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH (2011) Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129: 732-737. doi:10.1001/archophthalmol.2011.5.
9. Brodie SE, Paulus YM, Patel M, Gobin YP, Dunkel IJ, et al. (2012) ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma. Br J Ophthalmol 96: 877-880. doi:10.1136/bjophthalmol-2011-301248.
10. Liu CY, Jonna G, Francis JH, Marr BP, Abramson DH, et al. (2013) Non-selectivity of ERG reductions in eyes treated for retinoblastoma. Doc Ophthalmol: e-pubaheadofprint.
11. Wilson MW, Jackson JS, Phillips BX, Buchanan J, Frase S, et al. (2011) Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol 129: 1458-1465. doi:10.1001/archophthalmol.2011.330.
12. Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW (2013) Superselective Intraophthalmic Artery Chemotherapy in a Nonhuman Primate Model: Histopathologic Findings. JAMA Ophthalmol: 1-8. doi:10.1001/jamaophthalmol.2013.2065.
13. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, et al. (2012) Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology 119: 611-616. doi:10.1016/j.ophtha.2011.08.045.
14. Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA (2011) Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 114: 1603-1608. doi:10.3171/2011.1.JNS10466.
15. Vajzovic LM, Murray TG, Aziz-Sultan MA, Schefler AC, Wolfe SQ, et al. (2011) Supraselective intra-arterial chemotherapy: evaluation of treatmentrelated complications in advanced retinoblastoma. Clin Ophthalmol 5: 171-176. doi:10.2147/OPTH.S12665.
16. Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, et al. (2011) Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129: 1399-1406. doi:10.1001/archophthalmol.2011.150.
17. Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, et al. (2011) Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 129: 1407-1415. doi:10.1001/ archophthalmol.2011.151.
18. Munier FL, Beck-Popovic M, Balmer A, Gaillard M-C, Bovey E, et al. (2011) Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina (Philadelphia, Pa) 31: 566-573. doi:10.1097/IAE.0b013e318203c101.
19. Suzuki S, Yamane T, Mohri M, Kaneko A (2011) Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118: 2081-2087. doi:10.1016/j.ophtha.2011.03.013.
20. Venturi C, Bracco S, Cerase A, Cioni S, Galluzzi P, et al. (2012) Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments. Acta Ophthalmol. doi:10.1111/j.1755-3768.2011.02296.x.
21. Bianciotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P, et al. (2012) Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 119: 843-849. doi:10.1016/j.ophtha.2011.09.040.
22. Inomata M, Kaneko A (1987) Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 78: 858-868. (Pubitemid 17124771)
23. Ueda M, Tanabe J, Suzuki T, Sakai H, Mochizuki K, et al. (1994) [Conservative therapy for retinoblastoma-effect of melphalan on in vitro electroretinogram]. Nippon Ganka Gakkai Zasshi 98: 352-356.
24. Ueda M, Tanabe J, Inomata M, Kaneko A, Kimura T (1995) [Study on conservative treatment of retinoblastoma-effect of intravitreal injection of melphalan on the rabbit retina]. Nippon Ganka Gakkai Zasshi 99: 1230-1235.
25. Shimoda Y, Hamano R, Ishihara K, Shimoda N, Hagimura N, et al. (2008) Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy. Graefes Arch Clin Exp Ophthalmol 246: 501-508. doi:10.1007/s00417- 007-0685-3. (Pubitemid 351447962)
26. Friedrich S, Cheng YL, Saville B (1997) Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res 16: 663-669. (Pubitemid 27322718)
27. Munier FL, Gaillard M-C, Balmer A, Soliman S, Podilsky G, et al. (2012) Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. doi:10.1136/ bjophthalmol-2011-301450.
28. Nemeth KM, Federico S, Carcaboso AM, Shen Y, Schaiquevich P, et al. (2011) Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer 117: 421-434. doi:10.1002/cncr. 25574.
29. Buitrago E, Del Sole MJ, Torbidoni A, Fandino A, Asprea M, et al. (2013) Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Exp Eye Res 108: 103-109. doi:10.1016/j.exer.2013. 01.002.
30. Mallipatna AC, Dimaras H, Chan HSL, Héon E, Gallie BL (2011) Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 129: 738-745. doi:10.1001/archophthalmol.2011.130.
31. Kiratli H, Kocabeyoǧlu S, Bilgiç S (2007) Severe pseudo-preseptal cellulitis following sub-Tenon's carboplatin injection for intraocular retinoblastoma. J AAPOS 11: 404-405. doi:10.1016/j.jaapos.2006.11. 005. (Pubitemid 47198495)
32. Schmack I, Hubbard GB, Kang SJ, Aaberg TM, Grossniklaus HE (2006) Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 142: 310-315. doi:10.1016/j.ajo.2006.02.044.
33. Mulvihill A, Budning A, Jay V, Vandenhoven C, Héon E, et al. (2003) Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 121: 1120-1124. doi:10.1001/archopht.121.8.1120. (Pubitemid 36962165)
34. Lee TC, Hayashi NI, Dunkel IJ, Beaverson K, Novetsky D, et al. (2003) New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 110: 1989-94-discussion1994-5. doi:10.1016/S0161- 6420(03)00669-9.
35. Abramson DH, Frank CM, Dunkel IJ (1999) A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106: 1947-1950. doi:10.1016/S0161-6420(99)90406-2.
36. Van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM, et al. (2005) Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112: 1151-1158. doi:10.1016/j.ophtha.2004. 11.060. (Pubitemid 40797475)
37. Zlioba A, Peyman GA, Nikoleit J (1988) Retinal toxicity study of intravitreal carboplatin and iproplatin. Ann Ophthalmol 20: 71-72.
38. Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernández E, et al. (1996) Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 37: 1892-1898. (Pubitemid 26265041)
39. Pardue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, et al. (2004) Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina (Philadelphia, Pa) 24: 776-782. (Pubitemid 39391771)